As ER− status correlates with ERBB2 overexpression and poorly differentiated tumors [49], further studies are needed to determine if CA preferentially targets ER+ versus ER− BC cells, therefore providing a conceivable explanation for the differences observed in the two ERBB2+ cell lines. The gene discussed is ESR1; the disease is breast cancer.